News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA Questions Genzyme Corporation Knee Pain Treatment Study
December 5, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Dec 5 (Reuters) - A study of Genzyme Corp's latest version of its injectable knee pain treatment may not be strong enough to support the therapy, U.S. regulatory reviewers said in an analysis released on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
April 8, 2026
·
1 min read
·
Heather McKenzie
Insights
As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential
April 8, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Drug development
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
April 7, 2026
·
2 min read
·
Annalee Armstrong
Immunology and inflammation
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3
April 7, 2026
·
3 min read
·
Tristan Manalac
